Skip to main content

Advertisement

SpringerLink
Log in

The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease

  • Review
  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Background

Intravenous cyclosporine A (CsA) is an effective treatment for patients with severe, steroid-refractory ulcerative colitis (UC). Like the response to CsA, clinical trials have shown that two-thirds of patients with refractory UC respond to tacrolimus therapy. However, it is unclear how/when this agent should be used for patients with active UC.

Methods

We reviewed the results of previous studies regarding calcineurin inhibitors in UC patients. We examined the best way to use tacrolimus to obtain maximum efficacy by comparing the results from clinical trials with those from a recent survey in Japan.

Results

Calcineurin inhibitors are useful to induce remission in patients with refractory UC; however, the long-term prognosis has not been shown to be improved by CsA. Early intervention with CsA/tacrolimus may improve the long-term prognosis of UC patients just as infliximab does for Crohn’s disease patients. Recent studies have indicated that a fasting state and administration of a higher dosage of tacrolimus at the beginning of therapy are critical in ensuring that the target trough concentration of the agent is reached.

Conclusions

The use of higher initial doses of tacrolimus ensured that patients achieved their target levels. Further studies will be needed to elucidate the efficacy of top-down therapy with tacrolimus in patients with UC. Physicians must know how to use calcineurin inhibitors to obtain maximum efficacy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br Med J. 1955;2:104–8.

    Article  Google Scholar 

  2. Baron JH, Connell AM, Kanaghinis TG, Lennard-Jones JE, Jones AF. Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. Br Med J. 1962;2:441–3.

    Article  CAS  PubMed  Google Scholar 

  3. Sands BE. Immunosuppressive drugs in ulcerative colitis: twisting facts to suit theories. Gut. 2006;55:437–41.

    Article  CAS  PubMed  Google Scholar 

  4. Hanai H, Watanabe F, Takeuchi K, Iida T, Yamada M, Iwaoka Y, et al. Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin Gastroenterol Hepatol. 2003;1:28–35.

    Article  PubMed  Google Scholar 

  5. Hanai H, Watanabe F, Yamada M, Sato Y, Takeuchi K, Iida T, et al. Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digestion. 2004;70:36–44.

    Article  CAS  PubMed  Google Scholar 

  6. Naganuma M, Funakoshi S, Sakuraba A, Takagi H, Inoue N, Ogata H, et al. Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm Bowel Dis. 2004;10:251–7.

    Article  PubMed  Google Scholar 

  7. Sawada K, Kusugami K, Suzuki Y, Bamba T, Munakata A, Hibi T, et al. Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case–control study with sham apheresis as placebo treatment. Am J Gastroenterol. 2005;100:1362–9.

    Article  PubMed  Google Scholar 

  8. Emmrich J, Petermann S, Nowak D, Beutner I, Brock P, Klingel R, et al. Leukocytapheresis (LCAP) in the management of chronic active ulcerative colitis—results of a randomized pilot trial. Dig Dis Sci. 2007;52:2044–53.

    Article  CAS  PubMed  Google Scholar 

  9. Sands BE, Sandborn WJ, Feagan B, Löfberg R, Hibi T, Wang T, et al. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology. 2008;135:400–9.

    Article  CAS  PubMed  Google Scholar 

  10. Abraham C, Cho JH. Inflammatory bowel disease. New Engl J Med. 2009;361:2066–78.

    Article  CAS  PubMed  Google Scholar 

  11. Abbas AK, Lichtman AH. Activation of T lymphocytes. In: Malley J, editor. Cellular and molecular immunology. 5th ed. Philadelphia: Saunders; 2003.

  12. Mangan PR, Harrington LE, O’Quinn DB, Helms WS, Bullard DC, Elson CO, et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature. 2006;441:231–4.

    Article  CAS  PubMed  Google Scholar 

  13. McGeachy MJ, Cua DJ. The link between IL-23 and Th17 cell-mediated immune pathologies. Semin Immunol. 2007;19:372–6.

    Article  CAS  PubMed  Google Scholar 

  14. Lichtiger S, Present DH. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet. 1990;336:16–9.

    Article  CAS  PubMed  Google Scholar 

  15. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841–5.

    Article  CAS  PubMed  Google Scholar 

  16. D’Haens G, Lemmens L, Geboes K, Vandeputte L, Van Acker F, Mortelmans L, et al. Intravenous cyclosporin versus intravenous glucocorticosteroids as a single therapy for severe attacks of ulcerative colitis. Gastroenterology. 2001;120:1323–9.

    Article  PubMed  Google Scholar 

  17. Van Assche G, D’Haens G, Noman M, Vermeire S, Hiele M, Asnong K, et al. Randomized double-blind comparison of 4 mg/kg/day versus 2 mg/kg/day intravenous cyclosporin in severe ulcerative colitis. Gastroenterology. 2003;125:1025–31.

    Article  PubMed  Google Scholar 

  18. Moskovitz D, Van Assche G, Maenhout B, Arts J, Ferrante M, Vermeire S, et al. Incidence of colectomy during long term follow up after cyclosporin-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol. 2006;4:760–5.

    Article  CAS  PubMed  Google Scholar 

  19. Campbell S, Travis S, Jewell D. Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur J Gastroenterol Hepatol. 2005;17:79–84.

    Article  CAS  PubMed  Google Scholar 

  20. Arts J, D’Haens G, Zeegers M, Van Assche G, Hiele M, D’Hoore A, et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis. 2004;10:73–8.

    Article  PubMed  Google Scholar 

  21. Message L, Bourreille A, Laharie D, Quinton A, Galmiche JP, Lamouliatte H, et al. Efficacy of intravenous cyclosporin in moderately severe ulcerative colitis refractory to steroids. Gastroenterol Clin Biol. 2005;29:231–5.

    Article  CAS  PubMed  Google Scholar 

  22. Fernandez-Banares F, Bertran X, Esteve-Comas M, Cabre E, Menacho M, Humbert P, et al. Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Am J Gastroenterol. 1996;91:2498–9.

    CAS  PubMed  Google Scholar 

  23. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol. 1999;94:1587–92.

    Article  CAS  PubMed  Google Scholar 

  24. Kobayashi T, Naganuma M, Okamoto, Hisamatsu T, Inoue N, Ichikawa H, et al. 2010. Rapid endoscopic improvement is important for 1-year avoidance of colectomy but not for the long-term prognosis in cyclosporine A treatment for ulcerative colitis. J Gastroenterol (in press).

  25. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940–87.

    Article  CAS  PubMed  Google Scholar 

  26. Naganuma M, Ichikawa H, Inoue N, Kobayashi T, Okamoto S, Hisamatsu T, et al. Novel endoscopic activity index is useful for choosing treatment in severe active ulcerative colitis patients. J Gastroenterol. 2010;45:936–43.

    Article  PubMed  Google Scholar 

  27. Asshue GV, Vermeire S, Rutgeerts P. Treatment of severe steroid refractory ulcerative colitis. World J Gastroenterol. 2008;14:5508–11.

    Article  Google Scholar 

  28. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–76.

    Article  CAS  PubMed  Google Scholar 

  29. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:935–9.

    Article  PubMed  Google Scholar 

  30. Carter M, Lobo AJ, Travis SPL. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53(Suppl V):1–16.

    Article  Google Scholar 

  31. Järnerot G, Hertervig E, Friis-liby I, Blomquist L, Karlén P, Grännö C, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized placebo-controlled study. Gastroenterology. 2005;128:1805–11.

    Article  PubMed  Google Scholar 

  32. Fellermann K, Tanko Z, Herrlinger KR, Witthoeft T, Homann N, Bruening A, et al. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis. 2002;8:317–24.

    Google Scholar 

  33. Hogenauer C, Wenzl HH, Hinterleitner TA, Petritsch W. Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis. Aliment Pharmacol Ther. 2003;18:415–23.

    Article  CAS  PubMed  Google Scholar 

  34. Ogata H, Matsui T, Nakamura M, Iida M, Takazoe M, Suzuki Y, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut. 2006;55:1255–62.

    Article  CAS  PubMed  Google Scholar 

  35. Baumgart DC, Macdonald JK, Feagan B. Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. Cochrane Database Syst Rev. 2008;3:CD007216.

    PubMed  Google Scholar 

  36. Romano C, Comito D, Famiani A, Fries W. Oral tacrolimus (FK 506) in refractory paediatric ulcerative colitis. Aliment Pharmacol Ther. 2010;31:676–7.

    Article  CAS  PubMed  Google Scholar 

  37. Yamamoto S, Nakase H, Mikami S, Inoue S, Yoshino T, Takeda Y, et al. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther. 2008;28:589–97.

    Article  CAS  PubMed  Google Scholar 

  38. Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease—a long-term follow-up. Am J Gastroenterol. 2006;101:1048–56.

    Article  CAS  PubMed  Google Scholar 

  39. Ng SC, Arebi N, Kamm MA. Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:129–34.

    Article  PubMed  Google Scholar 

  40. Benson A, Barrett T, Sparberg M, Buchman AL. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn’s disease: a single-center experience. Inflamm Bowel Dis. 2008;14:7–12.

    Article  PubMed  Google Scholar 

  41. Baumgart DC, Wiedenmann B, Dignass AU. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment Pharmacol Ther. 2003;17:1273–81.

    Article  CAS  PubMed  Google Scholar 

  42. D’Haens G. Infliximab for ulcerative colitis: finally some answers. Gastroenterology. 2005;128:2161–6.

    Article  PubMed  Google Scholar 

  43. Herrlinger KR, Barthel DN, Schmidt KJ, Büning J, Barthel CS, Wehkamp J, et al. Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus. Aliment Pharmacol Ther. 2010;31:676–7.

    Article  Google Scholar 

  44. Yamamoto S, Nakase H, Matsuura M, Honzawa Y, Masuda S, Inui K, et al. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus. J Gastroenterol Hepatol. 2010;25:886–91.

    Article  CAS  PubMed  Google Scholar 

  45. Maser EA, Deconda D, Lichtiger S, Ullman T, Present DH, Kornbluth A. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin Gastroenterol Hepatol. 2008;6:1112–6.

    Article  CAS  PubMed  Google Scholar 

  46. Ng SC, Kamm MA. Therapeutic strategies for the management of ulcerative colitis. Inflamm Bowel Dis. 2009;15:935–50.

    Article  PubMed  Google Scholar 

  47. Travis SP, Stange EF, Lémann M, Oresland T, Chowers Y, Forbes A, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: current management. Gut. 2006;55(Suppl 1):i16–35.

    Article  PubMed  Google Scholar 

  48. D’Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet. 2008;371:660–7.

    Article  PubMed  Google Scholar 

  49. Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos M, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology. 2010;138:463–8.

    Article  PubMed  Google Scholar 

  50. Lichtiger S. Treatment of choice for acute severe steroid-refractory ulcerative colitis is cyclosporine. Inflamm Bowel Dis. 2009;15:141–2.

    Article  PubMed  Google Scholar 

  51. Sakuraba A, Sato T, Naganuma M, Morohoshi Y, Matsuoka K, Inoue N, et al. A pilot open-labeled prospective randomized study between weekly and intensive treatment of granulocyte and monocyte adsorption apheresis for active ulcerative colitis. J Gastroenterol. 2008;43:51–6.

    Article  PubMed  Google Scholar 

  52. Sakuraba A, Motoya S, Watanabe K, Nishishita M, Kanke K, Matsui T, et al. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol. 2009;104:2990–5.

    Article  PubMed  Google Scholar 

  53. Fukunaga K, Yokoyama Y, Kamikozuru K, Hida N, Ohda Y, Nakamura S, et al. A prospective randomized double blind sham controlled trial to assess the efficacy of monthly granulocyte/monocyte adsorption apheresis as maintenance therapy for patients with steroid refractory ulcerative colitis. Gut. 2010;59:A73.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, School of Medicine, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8513, Japan

    Makoto Naganuma, Toshimitsu Fujii & Mamoru Watanabe

Authors
  1. Makoto Naganuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Toshimitsu Fujii
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mamoru Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mamoru Watanabe.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Naganuma, M., Fujii, T. & Watanabe, M. The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease. J Gastroenterol 46, 129–137 (2011). https://doi.org/10.1007/s00535-010-0352-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00535-010-0352-z

Keywords

Search

Navigation